Objective To approach the clinical features of batched severe burn accompanied by blast injury in lungs, and to sum up both experiences and lessons drawn from the treatment on those cases. Methods 16 cases of severe burn accompanied by blast injury in lungs were inductively analyzed on their clinical features and the experiences and lessons drawn from the treatment were summed up. Results 14 cases got full recovery, and the 2 remainders died of multiple organ failure. Conclusion An overall treatment plan, evacuation in time and individual therapy are necessary for the batched treatment of severe burn accompanied by blast injury in lungs, and an integrated therapy may get a satisfied result.

Objective:To investigate the effect of multiple medications on the risk of small intestinal bacterial overgrowth(SIBO)in the elderly.Methods:Clinical data of 85 inpatients in the Department of Geriatrics, the First Hospital of Lanzhou University undergone HMBT from August 2017 to April 2021 were retrospectively analyzed.According to the HMBT results, they were divided into a SIBO(+ )group and a SIBO(-)group.Polypharmacy was defined as ≥ 5 types of medications.We analyzed the difference in the rate of polypharmacy between the two groups.Results:A total of 85 hospitalized elderly patients were included in the study.Of these patients, 38(44.71%)tested positive for SIBO.Polypharmacy occurred in 41 patients(48.24%). There were significant differences in types of drugs and polypharmacy between the SIBO(+ )group and the SIBO(-)group( t=3.01 and χ2=14.33, P<0.05 for both). Moreover, polypharmacy was a risk factor for SIBO( P=0.017, OR=10.85, 95% CI: 1.52-77.29). Among 14 commonly used drugs, gastrointestinal motility drugs were closely related to SIBO.There was a positive correlation between polypharmacy and the change in hydrogen levels at 90 min( P=0.040, r=0.22, 95% CI: 0.01-0.42). Conclusions:Polypharmacy is correlated with SIBO in the elderly, is a risk factor for SIBO and is helpful in clinical practice to assess the risk of SIBO and decide further examinations, contributing to early diagnosis and early treatment.

In order to adapt to the development of market economy, the original medical institutions run by state-owned enterprises have undergone restructuring reform, but these medical institutions have not fully played their role. Through the sampling survey and research interviews of several medical institutions run by state-owned enterprises, it was found that many problems such as unclear functional positioning, imperfect regional health planning, unclear responsible subjects and inadequate financial support hindered the development of medical institutions run by state-owned enterprises. In order to develop healthily, medical institutions run by state-owned enterprises need to cooperate with various parties to improve supporting policies, optimize their business environment, and build and improve the health service system.

Objective To prepare a nano drug(PFOB@Lip-MMC)with liposome as the carrier,liquid perfluorooc-tyl bromide(PFOB)as core and mitomycin C(MMC)loading on the liposome shell and study its inhibitory effect on the proliferation of human pterygium fibroblasts(HPFs).Methods The thin film dispersion-hydration ultrasonic method was used to prepare PFOB@Lip-MMC and detect its physical and chemical properties.Cell Counting Kit-8,Cam-PI cell viability staining and flow cytometry were employed to detect the impact of different concentrations of PFOB@Lip-MMC on the via-bility of HPFs.DiI fluorescence labeled PFOB@Lip-MMC was used to observe the permeability of the nano drug to HPFs under a laser confocal microscope.After establishing HPF inflammatory cell models,they were divided into the control group(with sterile phosphate-buffered saline solution added),PFOB@Lip group(with PFOB@Lip added),MMC group(with MMC added),PFOB@Lip-MMC group(with PFOB@Lip-MMC added)and normal group(with fresh culture medi-um added)according to the experimental requirements.After co-incubation for 24 h,flow cytometer was used to detect the apoptosis rate of inflammatory cells,and the gene expression levels of interleukin(IL)-1β,prostaglandin E2(PGE2),tumor necrosis factor(TNF)-α and vascular endothelial growth factor(VEGF)in cells were analyzed by PCR.Results The average particle size and Zeta potential of PFOB@Lip-MMC were(103.45±2.17)nm and(27.34±1.03)mV,respec-tively,and its entrapped efficiency and drug loading rate were(72.85±3.28)％and(34.27±2.04)％,respectively.The sustained-release MMC of drug-loaded nanospheres reached(78.34±2.92)％in vitro in a 24-hour ocular surface environ-ment.The biological safety of PFOB@Lip-MMC significantly improved compared to MMC.In terms of the DiI fluorescence labeled PFOB@Lip-MMC,after co-incubation with inflammatory HPFs for 2 h,DiI fluorescence labeling was diffusely dis-tributed in the cytoplasm of inflammatory HPFs.The apoptosis rate of inflammatory HPFs in the PFOB@Lip-MMC group[(77.23±4.93)％]was significantly higher than that in the MMC group[(51.62±3.28)％].The PCR examination results showed that the gene transcription levels of IL-1 β,PGE2,TNF-α and VEGF in other groups were significantly reduced com-pared to the control group and PFOB@Lip group,with the most significant decrease in the PFOB@Lip-MMC group(all P＜0.05).Conclusion In this study,a novel nano drug(PFOB@LIP-MMC)that inhibited the proliferation of HPFs was successfully synthesized,and its cytotoxicity was significantly reduced compared to the original drugs.It has good bio-compatibility and anti-inflammatory effects,providing a new treatment approach for reducing the recurrence rate after pte-rygium surgery.